Shareholders to help Pacific Edge commercialise cancer research
Dunedin-based Pacific Edge Biotechnology is forging ahead to commercialise its bladder cancer test, and its preferred funding option is to ask existing shareholders for some of up to $6 million estimated for the task.Pacific Edge…
Read more on The New Zealand Herald
